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Background: Accurate and precise quantification of
mRNA in whole blood is made difficult by gene expres-
sion changes during blood processing, and by variations
and biases introduced by sample preparations. We
sought to develop a quantitative whole-blood mRNA
assay that eliminates blood purification, RNA isolation,
reverse transcription, and target amplification while
providing high-quality data in an easy assay format.
Methods: We performed single- and multiplex gene
analysis with multiple hybridization probes to capture
mRNA directly from blood lysate and used branched
DNA to amplify the signal. The 96-well plate singleplex
assay uses chemiluminescence detection, and the mul-
tiplex assay combines Luminex-encoded beads with
fluorescent detection.
Results: The single- and multiplex assays could quan-
titatively measure as low as 6000 and 24 000 mRNA
target molecules (0.01 and 0.04 amoles), respectively, in
up to 25 L of whole blood. Both formats had CVs
<10% and dynamic ranges of 3–4 logs. Assay sensitivi-
ties allowed quantitative measurement of gene expres-
sion in the minority of cells in whole blood. The signals
from whole-blood lysate correlated well with signals
from purified RNA of the same sample, and absolute
mRNA quantification results from the assay were sim-
ilar to those obtained by quantitative reverse transcrip-
tion-PCR. Both single- and multiplex assay formats
were compatible with common anticoagulants and PAX-
gene-treated samples; however, PAXgene preparations
induced expression of known antiapoptotic genes in
whole blood.
Conclusions: Both the singleplex and the multiplex
assays can quantitatively measure mRNA expression
directly from small volumes of whole blood. The assay
offers an alternative to current technologies that depend
on RNA isolation and is amenable to high-throughput
gene expression analysis of whole blood.
© 2006 American Association for Clinical Chemistry
The validity and reproducibility of mRNA quantification
in peripheral blood affect the potential clinical application
of biomarker research (1). Limitations of technologies
commonly used in peripheral blood gene expression
analysis have hindered the wider application of genomics
advances in the clinic (2), (3), and gene expression anal-
ysis in peripheral blood remains a challenge (4).
Changes in gene expression during preanalytical han-
dling are a major difficulty unique to peripheral blood
mRNA analysis (5–9). The blood-stabilizing reagent PAX-
gene was developed to prevent RNA degradation and
time-dependent ex vivo induction of cytokines and im-
mediate early-response genes (5). An overall gene expres-
sion pattern distinct from regular blood leukocytes is
found in PAXgene-stabilized blood (10), and it has yet to
be determined whether PAXgene reagent induces expres-
sion changes in blood samples (5).
Accurate and precise quantification of mRNA in whole
blood is made even more difficult by dependence on RNA
purification and subsequent enzymatic manipulation.
Standard RNA extractions from fresh or stabilized whole
blood give RNA of variable yield and quality, which may
lead to inconsistent gene expression patterns (10–12).
Indeed, although technologies such as microarrays and
quantitative real-time PCR (RT-PCR)
1 are highly repro-
ducible, their overall effectiveness has been hampered by
inherent variations in sample preparation steps (13–16).
Of particular concern is the potential bias caused by
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nologies.
An assay technology that involves minimal blood
processing and does not require blood RNA isolation and
enzymatic manipulation might overcome these challenges
in blood gene expression analysis. Direct detection of
target RNA in cell culture lysates has been described
(18, 19), but these methods have not been successfully
applied to whole-blood analysis,
Sandwich hybridization coupled with signal instead of
target amplification can bypass RNA isolation and label-
ing while achieving sufficient sensitivity. We report the
development of a direct whole-blood RNA quantification
method using branched DNA (bDNA) signal amplifica-
tion technology (Bayer). bDNA is a hybridization-based
method that uses multiple oligonucleotide probes to cap-
ture target RNA and multiple branched DNA multimers
to amplify the signal (20). The technology has been
cleared by the US Food and Drug Administration for use
in detecting HIV and hepatitis C virus mRNAs from viral
particles purified from plasma (20, 21), and it has also
been used to directly detect RNA in cell culture lysates
(22). Initial attempts to apply bDNA to whole blood were
unsuccessful, however, and partially purified RNA from
the mononuclear fraction had to be used (23). Our bDNA
method directly measures the RNA in whole-blood ly-
sates.
Materials and Methods
singleplex assay for whole blood
Fresh, anticoagulated (EDTA, heparin, or citrate as anti-
coagulant) blood from healthy donors obtained under
Institutional Review Board–approved guidelines from
Stanford Blood Center (Stanford, CA) was refrigerated
and assayed within 1 h after blood draw. We added 1 to
25 L of whole blood to lysis solution to a final volume of
150 L containing 50% blood lysis buffer [200 mmol/L
LiCl, 50 g/L lithium lauryl sulfate, 9 mmol/L EDTA, 50
mmol/L HEPES (pH 7.5), 2 g/L casein] and 1 g/L
proteinase K. The mixture was shaken at 1200 rpm and
60 °C for 0.5 h in a heated shaker to lyse the cells. The
blood lysate was assayed immediately or stored at 80 °C
for months for later use. Target gene probe sets containing
150, 300, and 600 fmol of capture extender probe (CE),
blocking probe, and label extender probe (LE), respec-
tively, were added to the blood lysate, and the lysate was
transferred to an assay well in a 96-well plate covalently
coated with Capture Probe oligo (5-CACTTCACTT-
TCTTTCCAAGAG-3) and incubated for 16 h at 58 °C.
Wells were washed 3 times with 200 L of wash buffer
(0.1 standard saline citrate containing 3 g/L lithium
lauryl sulfate), followed by sequential hybridizations at
53 °C for 1 h with 100 L of a 1:1000 dilution of bDNA
amplifier (Bayer Diagnostics) and 46 °C for 1 h with 100
L (50 fmol) of 3-alkaline phosphatase–conjugated Label
Probe oligo (5-AAGTACGACAACCACATC-3), with 3
washes after each incubation. After a final wash, the
alkaline phosphatase substrate dioxetane (Bayer Diagnos-
tics) was added to the wells and incubated at 46 °C for 30
min to develop the luminescent signal, which was de-
tected with an Lmax microtiter plate luminometer (Mo-
lecular Device).
singleplex assay for PAXgene-stabilized blood
PAXgene-stabilized blood was prepared according to the
manufacturer’s protocol (PreAnalytiX); 9.5 mL of stabi-
lized blood is equivalent to 2.5 mL of whole blood. After
storage for 16 h at room temperature, the stabilized blood
was centrifuged for 5 min at 3000g. The supernatant was
removed by decanting or pipetting. The pellet was se-
quentially washed with H2O (1000 L/mL of stabilized
blood) and 2 mol/L LiCl (400 L/mL of stabilized blood)
before being lysed at 60 °C with shaking for 30-min in
T&C Lysis Solution (Epicentre; 265 L/mL of stabilized
blood) with 0.25 g/L proteinase K. Lysate was assayed
immediately or stored at 80 °C for later use. We mixed
1t o3 0L of lysate, corresponding to same volume of the
original whole blood, with 75 L of blood lysis buffer and
H2O to a final volume of 150 L. Target gene probe sets
containing 150, 300, and 600 fmol of CE, blocking probe,
and LE, respectively, were added to the lysate. The
mixture was transferred to an assay well in a 96-well plate
coated with capture probes and incubated for 16 h at
58 °C. Subsequent steps were the same as after the 16-h
hybridization step described for the singleplex assay for
whole blood.
multiplex assay
A panel of oligonucleotide capture probes, each with a
unique sequence of 15 bases, were synthesized with
5-amino linker (BioSearch), and each was covalently
linked to carboxylated fluorescently encoded beads (Lu-
minex) according to the recommended conjugation pro-
cedure. Beads conjugated with different capture probes
were pooled in equal proportions before use. We mixed
100 L of whole-blood lysates or PAXgene blood lysates
prepared as above with the multiplex panel probe sets
and the pooled capture beads (2000 beads of each type) in
a round-bottomed assay well and hybridized for 16 h at
58 °C (final volume in each well, 110 L). The assay
mixture was transferred to a MultiScreen filter plate
(Millipore), and unbound material was filter-washed
from the wells by washing 3 times with wash buffer. The
plate was then hybridized at 53 °C for 1 h with 100
L/well of a 3:1000 dilution of bDNA amplifier in ampli-
fier diluent [3 mol/L tetramethylammonium chloride, 1
mL/L Sarkosyl, 50 mmol/L Tris-HCl, 4 mmol/L EDTA,
40 g/L dextran sulfate, 10 g/L bovine serum albumin, and
5 mL/L Micr-O-protect (Roche Molecular System)]. After
the plate was filter-washed twice with wash buffer, it was
incubated at 46 °C for 1 h with 100 L/well of 150 fmol
5-dT(Biotin)-conjugated label probe (Biosearch) diluted
in Amplifier diluent without the dextran sulfate. After 2
washes, streptavidin-conjugated R-phycoerythrin (SA-PE;
2 Zheng et al.: Direct Gene Expression Measurement from Whole BloodProzyme) at 6 mg/L diluted in SA-PE diluent (20 mmol/L
Tris-HCl, 400 mmol/L lithium chloride, 1 mL/L Tween
20, 1 mL/L bovine serum albumin, and 5 mL/L Micr-O-
protect) was added, and the plate was incubated at room
temperature for 30 min. We washed the beads to remove
unbound SA-PE and then analyzed them with the Lumi-
nex 100IS (Luminex) or Bio-Plex (Bio-Rad) system. The
SA-PE fluorescence measured from each bead was pro-
portional to the number of mRNA transcripts captured by
the beads.
lipopolysaccharide stimulation of whole
blood and absolute mRNA quantification by
multiplexed assay or quantitative real-time
pcr
We incubated fresh heparinized whole blood (Stanford
Blood Center), with or without added 10 mg/L Escherichia
coli lipopolysaccharide (LPS; Sigma), at 37 °C with mild
shaking in a cell culture incubator for 30–125 min. Ali-
quots were removed and either lysed and assayed in
multiplex according to the method described above or
processed for total RNA extraction with a QIAamp RNA
Blood Mini Kit (Qiagen) with on-column DNase diges-
tion.
We prepared in vitro transcripts from commercial
cDNA clones with sequences covering regions of the
designed probes and the TaqMan amplicon. Purified
transcripts were quantified with a Quan-iT RiboGreen
RNA Assay Kit (Molecular Probes). We prepared a stock
solution of 10 human cytokine and housekeeping gene
transcripts mixed to a final concentration of 32 amol/L
each in 0.1 g/L yeast tRNA. Before gene quantification
experiments, the stock solution was serially diluted 4-fold
in 0.1 g/L yeast tRNA to generate a series of RNA
calibrators.
For RNA quantification with multiplex assays, RNA
calibrators from in concentrations from 40 to 0.01 amoles
were assayed under conditions identical to the assays
with whole-blood (20 L) lysates. We obtained the RNA
quantities (in attomoles) from the fluorescence intensities
after fitting the calibration curve with the 5-parameter
logistics algorithm provided by the Luminex instrument
software package.
To determine RNA copy numbers by quantitative
PCR, we reverse-transcribed 1 L each of the RNA cali-
brators containing 32 to 0.008 amoles, as well as equi-
valent RNA (by volume) from 20 L of whole blood,
in 10-L reactions with TaqMan reverse transcription
reagents with random primers (Applied Biosystems).
cDNA was amplified and detected in a Mx4000 PCR
System (Stratagene) with TaqMan Universal PCR master
mixture and TaqMan probes [Hs00174128_m1 for tumor
necrosis factor (TNF),
2 Hs99999903_m1 for interleukin-1
(IL1B), and Hs00173626_m1 for vascular endothelial
growth factor (VEGF); Applied Biosystems]. Each sample
was reverse-transcribed in duplicate and each cDNA
PCR-amplified in duplicate. The calibrations curves
[threshold cycle vs log(copy number)] generated all have
R
2 values 0.999. RNA copy numbers were calculated
from threshold cycle values by use of the corresponding
calibration curve.
erythrocyte lysis and total rna extraction
Erythrocytes in whole blood were lysed in erythrocyte
lysis solution (Epicentre) according to the recommended
protocol. After brief centrifugation, the supernatant was
removed and the pellet resuspended in phosphate-buff-
ered saline to the original volume of whole blood. Total
RNA from whole blood or blood containing lysed eryth-
rocytes was extracted with TriReagent BD (Molecular
Research Center) according to the recommended protocol.
probe design for single- and multiplex assays
We developed modified probe design software (24) to
design probe sets for target genes in both single- and
multiplex assays. For each target sequence, the software
algorithm identified regions that could serve as annealing
templates for CEs (5–7 per gene), LEs (10–15 per gene), or
blocking probes. CE-LE, CE-bDNA, CE-label probe, and
LE-capture probe interactions having highly negative G
values were removed to minimize nonspecific hybridiza-
tion. The probe sets were essentially the same for both the
single- and multiplex assays except for the portion of the
CE probes that hybridized with the capture probe. We
developed three 10-plex panels for the study of signal
correlations between lysate and RNA. Probe sequences for
each gene tested are listed in Table 1 of the Data Supplement
that accompanies the online version of this article at http://
www.clinchem.org/content/vol52/issue7/.
data analysis and statistics
Three replicate assays (n  3) were performed for all
described experimental samples unless noted otherwise.
For all samples, background signals in the absence of
target mRNAs were determined and subtracted from
2 TNF, tumor necrosis factor (TNF superfamily, member 2); IL1B, interleu-
kin-1; VEGF, vascular endothelial growth factor; IL2, interleukin-2; IL8,
interleukin-8; IL6, interleukin-6; CFLAR, CASP8 and FADD-like apoptosis
regulator; EIF1, eukaryotic translation initiation factor 1 (also known as SUI1);
GAPDH, glyceraldehyde-3-phosphate dehydrogenase; ACTB, actin, beta;
IFNG, interferon, gamma; CSF2, colony stimulating factor 2 (granulocyte-
macrophage); RELB, v-rel reticuloendotheliosis viral oncogene homolog B,
nuclear factor of kappa light polypeptide gene enhancer in B-cells 3 (avian);
CDKN1A, cyclin-dependent kinase inhibitor 1A (p21, Cip1); NFKB1, nuclear
factor of kappa light polypeptide gene enhancer in B-cells 1 (p105); NFKB2,
nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p49/
p100); RELA, v-rel reticuloendotheliosis viral oncogene homolog A, nuclear
factor of kappa light polypeptide gene enhancer in B-cells 3, p65 (avian);
NFKBIA, nuclear factor of kappa light polypeptide gene enhancer in B-cells
inhibitor, alpha; BAK, BCL2-antagonist/killer; FASL, Fas ligand; FAS, Fas (TNF
receptor superfamily, member 6); PTK2B, protein tyrosine kinase 2 beta (also
known as RAFTK), BAD, BCL2-antagonist of cell death; BCL2, B-cell CLL/
lymphoma 2; IL6R, interleukin-6 receptor; BCL2L1, BCL2-like 1 (also known as
BCL-XL).
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obtain the net signal. Statistical significance of biological
studies was tested with a two-tailed Student t-test. The
limit of detection was determined as the amount of target
in vitro transcript added to the assay that gave a net signal
3 times higher than the SD of the blank control.
Results and Discussion
overview of the assay
The technology quantifies mRNA by hybridizing 20
independent oligonucleotide probes to 500–600 contigu-
ous bases of target sequence. The assay amplifies the
detection signal with bDNA multimers (Fig. 1). The
multiple-probe-per-target design takes advantage of the
fact that the interactions between contiguous probes and a
target lead to stronger, more stable helix formation be-
cause of a base-stacking effect (25). In addition, the
“multidentate” interaction between the many capture
probes on the solid surface and the multiple CEs bound to
1 target leads to stronger capture than any single-capture
probe–CE interaction alone.
assay performance
Interference from blood constituents such as proteins,
DNA, and reticulocytes and high ribonuclease activity
make quantifying RNA directly from whole blood diffi-
cult (26). The original bDNA reagents and protocols from
Bayer had high background and did not completely
inhibit ribonuclease activity (data not shown). Lysis buff-
ers based on chemotropic agents such as guanidine salts,
however, interfere with subsequent hybridization and
target capture. We therefore developed a lysis buffer and
protocol (see Materials and Methods) that ensure complete
inhibition of RNase activity while promoting robust and
specific hybridization. To reduce the nonspecific assay
background, we took advantage of the enhanced interac-
tion between the capture surface (plate or bead) and the
many CEs bound to one target (Fig. 1). We increased the
hybridization temperature to destabilize the hybridiza-
tion between a single CE and a surface capture probe
while not affecting the stability of the multidentate inter-
action between the surface and multiple CEs. This modi-
fication improved the assay specificity. In addition, we
limited the blood volume to no more than 25% of the final
lysate and optimized assay conditions to maximize the
signal-to-noise ratio.
To determine the analytical sensitivity and specificity
of the optimized assay, we added increasing amounts of
exogenous in vitro transcripts (IVTs) from E. coli dapB (not
present in whole blood) during the lysis of a fixed volume
of whole blood. Compared with IVT-only controls, exog-
enous transcript recovery rates from the whole-blood
lysate were nearly 100% of known amounts (see Fig. 1a in
the online Data Supplement). The assay signal was pro-
portional to the amount of IVT in blood lysates. The assay
can quantitatively measure as few as 6000 copies (0.01
amole) of target mRNA with a dynamic range spanning
more than 3 logs, in the presence of a complex mixture
from 25 L of blood consisting of 0.2  10
6 leukocytes
and 0.1  10
9 erythrocytes. We obtained a similar result
by adding transcripts of interleukin-2 (IL2) that were not
detectable in unstimulated whole blood (data not shown).
When a fixed amount of IVT was assayed in the presence
of increasing amount of blood lysates, the signals were
similar (see Fig. 1b in the online Data Supplement),
suggesting that nonspecific RNA or protein in blood
lysates did not interfere with the assay. For detection of
endogenous blood mRNA, we obtained quantitative re-
sponses for a variety of blood cell markers in up to 25 L
of whole blood (Fig. 2). The mean CV (representing data
from 56 assays run in triplicate) was 5% (range, 0.3%–
18%). The mean interrun CV was 9% (range, 0.4%–35%).
Because blood cells were lysed and RNase was inacti-
vated, the lysate can be stored long-term without degra-
dation at 80 °C for future use (data not shown). Whole
blood drawn into EDTA, citrate, heparin, and PAXgene-
Fig. 1. Schematic of the assay.
(A), for each mRNA target, a set of oligonucleotide probes capable of hybridizing a contiguous regions of the target mRNA molecule is designed. Among these probes,
some contain a common extension “tail” sequence that is independent of the target sequence but can interact with the solid support. These probes are called capture
extenders (CE). Other probes contain a different common tail sequence that can interact with the detection system and are called label extenders (LE). The remaining
probes containing only target specific sequences are called blockers (BP or BL). After cells are lysed and released mRNAs hybridize with their probes, multiple
mRNA-bound capture extender tails hybridize to the complementary capture probes (CP) covalently attached to the solid support, leading to the capture of mRNA to
the solid support. (B), a bDNA molecule (20) is then applied and hybridized to the tails of the label extenders. The brances of the molecule hybridize to oligonucleotide
probes labeled with alkaline phosphatase (as shown, for singleplex) or biotin (for multiplex). (C), chemiluminescence (as shown, for singleplex) or fluorescence
(multiplex) detection is used to measure signals generated from labeled probes after the luminescent substrate dioxetane (as shown, for singleplex) or fluorescent
SA-PE (for multiplex) is added. The solid support is the surface of either a well (singleplex) or color-encoded bead (multiplex).
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tested (data not shown). Under the assay conditions,
genomic DNA in the lysate remained double-stranded:
probes for complementary strands did not produce a
signal (Fig. 2A). These probes produced signals only
when we used cDNA as the target (data not shown).
These results indicate that the assay allows sensitive,
specific, and direct quantification of RNA, without inter-
ference from blood constituents such as proteins, DNA,
and the high concentrations of nonspecific RNAs.
In contrast to microarrays and RT-PCR, which rely on
single-probe–target interaction for target capture or detec-
tion, our assay uses, on average, 20 probes (see Table 1 in
the online Data Supplement) that hybridize to 500–600
contiguous bases of 1 target sequence. Under optimized
assay conditions, both the capture and detection probes
must hybridize to the same RNA molecule to produce a
signal, and binding of multiple capture probes to the same
RNA target is required for RNA capture on the solid
surface. These conditions ensure high specificity of the
assay in the complex mixture of whole-blood lysate. The
assay also takes advantage of stronger, more stable helix
formation from hybridization of contiguous probes to a
target (25), which leads to improved target capture and a
lower assay CV. In the singleplex assay, 90% of the
target molecules were captured on the solid surface, as
indicated by the minimal signals from a second assay
measuring the unbound supernatant (data not shown).
The mean CV for replicate blood samples was routinely
10%. In comparison, the reported CV for replicate blood
samples in microarray analysis is 37% (10), and for
TaqMan RT-PCR, the reported CV for copy numbers from
replicate PAXgene-treated blood is 16% (5). Thus, our
singleplex assay can efficiently detect gene expression in
as little as 5 L of whole blood, even for RNA expressed
only in the minority blood cell types, such as natural killer
cells and B cells (both 300 cells/L blood; Fig. 2C).
To simultaneously detect several distinct mRNAs in
whole-blood lysate, we developed a multiplexed assay
based on a Luminex bead–based multiplex platform (27)
with modifications for higher stringency (see Materials and
Methods). Target-specific hybridization occurs on the sur-
face of different internally color-coded microbeads. When
analyzed on the Luminex 100 IS flow system, the color
code of each bead identifies the target gene being assayed,
and the fluorescent intensities on the beads measure
target concentration.
When we added increasing amounts of in vitro–trans-
cribed dapB RNA to a constant volume of whole-blood
lysate (25 L), the signals were similar to those for IVT
without lysate, and the specific responses in the presence
and absence of whole blood showed good linearity, as in
the singleplex plate assay (see Fig. 2 in the online Data
Supplement). The multiplexed assay has a detection limit
of 0.01–0.04 amoles (6000–24 000 copies) of target mole-
cules in the complex mixture from up to 25 L of whole
blood, with a mean CV of 8.1%. The lower sensitivity
relative to the singleplex assay is partly attributable to the
Fig. 2. Quantitative singleplex detection of mRNA in whole blood.
Fresh, heparinized whole blood was lysed and assayed for glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) and various cell marker genes indicated (A–C)
by use of specific probes. The means CVs were 6% (A), 5% (B), and 7% (C). No
signal from genomic DNA can be detected by probes designed to bind the
antisense strand of GAPDH (Œ in panel A). Mean (SD; error bars) results are
shown. NK, natural killer. RLU, relative light unit(s). Signal at limit of detection is
0.1 RLU.
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chemiluminescence detection. We validated the multiplex
assay by profiling multiple cytokine mRNAs in LPS-
stimulated whole blood. Expression of IL1B, interleukin-8
(IL8), interleukin-6 (IL6), and TNF was significantly in-
duced by LPS (Fig. 3), consistent with a previous report
(28). In addition, VEGF expression in whole blood was
induced by LPS. Quantitative signals were detected in the
lowest volume tested (4 L; see Fig. 3 in the online Data
Supplement). Interestingly, ex vivo incubation at 37 °C
alone (no LPS) caused significant basal induction of IL1B,
IL8, and TNF mRNA expression (Fig. 3), consistent with
whole-blood responsiveness to environmental conditions.
To confirm that results from whole-blood lysate accu-
rately represent RNA expression, we used phenol–chlo-
roform to extract total RNA and assayed both the lysate
and the purified RNA from the same sample for a group
of cytokine and apoptosis genes whose copy numbers can
be easily affected by sample handling (29). Because no
RNA isolation procedure can extract sufficient RNA from
25 L of blood, we extracted 1 mL of whole blood and
used an equivalent amount of RNA in the multiplex
bDNA assay. We obtained good correlation between
signals from whole-blood lysates and purified total RNA
(Fig. 4A), which suggests that direct measurement is a
reliable alternative to traditional methods of measuring
isolated RNA. However, the signals from direct lysates
were 3- to 10-fold stronger than those of purified RNA
from equivalent amounts of blood (Fig. 4A and data not
shown). The higher signals were not attributable to inter-
ference from erythrocytes because we obtained similar
signals from lysates of blood containing lysed erythro-
cytes (Fig. 4B). Instead, the lower signals in RNA samples
appeared to be attributable to RNA loss during the
phenol–chloroform purification procedure, because the
signals were similar after normalization against an exog-
enous transcript added to the lysate before RNA extrac-
tion (data not shown). Thus, the assay can reliably quan-
tify multiple mRNAs directly from small volumes of
whole blood.
Because the assay directly measures target RNA with
the same hybridization efficiency for blood lysates and
Fig. 3. Quantitative multiplex detection of mRNA
in whole blood.
Fresh heparinized whole blood (100 L) was incubated
at 37 °C for 60 min with or without 10 mg/L LPS. To
quantify cytokine gene expression with the multiplex
assay, 13 L was removed. Control (f) is blood sample
at t  0.  indicates significant difference from control
(P 0.01). Means (SD; error bars) are shown. MFI,
mean fluorescence intensity. Signal at the limit of
detection is 2.5 MFI.
Fig. 4. Correlation of multiplex assay signals.
(A), correlation of signals from whole-blood (20 L) lysate and from RNA of the same sample. Genes assayed in multiplex included TNF, IL10, IL6, IL1B, IFNG, IL8, CSF2,
GAPDH, RELB, A20, CDKN1A, NFKB1, NFKB2, RELA, NFKBIA, BAK, FASL, FAS, PTK2B, BAD, BCL2, IL6R, BCL2L1, ACTB, and CFLAR. Equivalent RNA from 160 Lo f
whole blood was assayed to yield sufficient signals for most genes. Good correlation was evident except for signals approaching the limit of detection. The slope of
the linear regression is 2.34, substantially lower than the expected slope of 8, suggesting RNA loss during phenol-chloroform extraction. (B), correlation of signals from
lysates of whole blood and erythrocyte-lysed blood (both 20 L). Erythrocyte lysis did not significantly change the expression of the genes listed for panel A, except
for the substantial reduction BCL2L1, a gene expressed in erythrocytes that plays an important role in erythropoiesis (35). The loss of BCL2L1 signal thus verified
successful erythrocyte lysis. The slope of the linear regression line, excluding BCL2L1 (outlier in panel B), is 0.86, close to the expected slope of 1. MFI, median
fluorescence intensity.
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Supplement), it enables absolute quantification of mRNA
by use of calibration curves constructed with known
amounts of RNA target transcripts. We demonstrated this
capability by direct, multiplexed absolute quantification
of 3 cytokine mRNAs in whole blood (see Materials and
Methods) and compared those results with results ob-
tained with the TaqMan RT-PCR method (Table 1). We
used the same blood samples and RNA calibrators for
both methods, and the results were in good agreement
(R
2  0.999; see Fig. 4 in the online Data Supplement),
with similar values and precisions (Table 1). However,
because the multiplex assay did not involve RNA purifi-
cation or enzymatic reactions and has the ability to
measure multiple genes and construct multiple calibra-
tion curves simultaneously, it has substantially higher
sample throughput, is less labor-intensive, and requires
smaller amounts of sample and assay reagents than does
RT-PCR.
assessment of the effect of PAXgene
stabilization on blood gene expression
Earlier reports suggested that blood stabilization by PAX-
gene is a slow process that may affect gene expression
(10–12). However, interference by excessive amounts of
globin mRNA in reticulocytes made comprehensive mi-
croarray comparison of fresh and stabilized whole blood
impossible (10). Because our assay directly measures
blood RNA expression and is not affected by excessive
globin mRNA, we were able to assess the impact of
PAXgene on blood gene expression. We purified total
RNA with the PAXgene reagents and assayed both the
lysate and the PAXgene-purified RNA from the same
sample for the stress-sensitive genes mentioned above
(see legend for Fig. 4A). We found that PAXgene treat-
ment led to significant changes in gene expression com-
pared with direct whole-blood measurement (Fig. 5).
Antiapoptosis genes such as CASP8 and FADD-like apo-
ptosis regulator (CFLAR) are induced by PAXgene re-
agent (see Fig. 5 in the online Data Supplement), whereas
in direct lysates, lysates of erythrocyte-lysed blood, and
phenol-purified RNA, normalized expression was compa-
rable (Fig. 4). Other genes, such as eukaryotic translation
initiation factor 1 (EIF1), a stress-inducible translation
initiation factor (30), were not induced in PAXgene blood
(see Fig. 5 in the online Data Supplement), suggesting that
the induction was relatively specific to apoptosis genes.
An additional experiment assaying lysates of nucleic acid
pellets formed in PAXgene blood (see Materials and Meth-
ods) also confirmed these results, indicating that increased
amounts of these apoptosis genes are not artifacts of RNA
extraction.
These observations agree with the finding that PAX-
gene treatment of human bone marrow aspirates induces
gene expression (31). Thus, for biomarker discovery, to be
certain that the gene of interest is not affected by PAX-
gene, we recommend validation directly from blood with-
out PAXgene treatment, particularly if the identified
candidate biomarkers include CFLAR (32) or other apo-
ptosis genes.
Blood biomarker studies often involve microarray pro-
filing on a limited number of samples, followed by
validation of dozens of genes in larger cohorts. Our
singleplex and multiplex assays are both useful as fol-
low-up assays for microarray validation. They have better
sensitivity, precision, dynamic range, and sample
throughput capability than microarrays, and the assay
time from blood collection to mRNA detection is shorter.
The Luminex bead platform enables simultaneous detec-
tion of up to 100 genes, a number that could be increased
substantially by adapting the assay to higher multiplex
formats. With minimal amounts of blood and processing
required and no need to purify, label, or amplify the RNA
targets, this assay overcomes many problems currently
associated with gene expression profiling of whole blood
(2, 10, 33).
Fig. 5. Effect of PAXgene treatment on gene expression.
Correlation of multiplexed assay signals from whole blood (20 L) lysate and
from purified RNA of the same blood sample stabilized in PAXgene. mRNAs
examined are listed in Fig. 4A. Equivalent RNA from 160 L of whole blood
stabilized in PAXgene was assayed to yield sufficient signals for most genes. The
slope of the linear regression is 0.68, substantially lower than the expected
slope of 8. MFI, median fluorescence intensity.
Table 1. Comparison of absolute mRNA quantification
results.
a
mRNA Blood sample
Mean (SD) concentration, amoles
Multiplex
Quantitative
PCR
TNF Control 0.091 (0.006) 0.028 (0.003)
LPS-treated 1.66 (0.12) 1.45 (0.18)
VEGF Control 0.016 (0.007) 0.022 (0.001)
LPS treated 0.15 (0.01) 0.41 (0.05)
IL1B Control 0.30 (0.03) 0.13 (0.03)
LPS treated 14.4 (0.56) 12.6 (1.5)
a Copies of TNF, VEGF, and IL1B mRNA in 20 L of fresh whole blood (control)
or whole blood incubated with 10 mg/L LPS at 37
oC for 60 min (LPS-treated)
were determined either from whole blood lysates by the multiplex assay or from
purified RNA by TaqMan quantitative PCR assay. See Materials and Methods for
details. 1 amole  6.02  10
5 copies.
Clinical Chemistry 52, No. 7, 2006 7This assay also has several advantages over quantita-
tive PCR, including no required RNA purification steps,
the ability to multiplex, higher sample throughput, the
ability to use much smaller volumes of blood, and overall
better accuracy and precision because of direct measure-
ment of target RNA. With the current design, the assay
can directly detect as few as 6000 copies of target RNA.
This detection limit is slightly higher than that of quanti-
tative PCR. There are several ways the assay’s detection
limit can be lowered. One approach is to design addi-
tional LE probes per target to increase the number of
bDNA amplifiers used to generate the signals. This ap-
proach is limited only by the assay cost. Another, more
efficient approach is to improve signal amplification effi-
ciency, e.g., by including “preamplifier” oligonucleotides
that link each LE with multiple amplifier molecules (34).
In summary, this method can simplify clinical gene ex-
pression analysis. RNA analysis can be performed with
only a limited amount of blood, and the elimination of
RNA purification is particularly useful for large-scale stud-
ies, for which sample throughput has been limited by
laborious RNA purification or insufficient RNA yield. Taken
together, the simple workflow, exceptional accuracy, and
consistency of the results give this assay advantages over
others for whole-blood gene expression analysis.
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